8 trends in life sciences investment this week
From 29 October 2026 to 4 November 2026, 10 biotech and health care companies reported $39.0 million of new private money in SEC Form D filings (company count down 57% on the 4-week average of 23.0), and companies registered 662 new trials, 290 of them at Phase 3.
As of . Research from public records, not investment advice.
- Venture money into biotech and health care: 10 operating companies reported Form D sales, $39.0 million in total. Companies down 57% on the 4-week average of 23.0; money down 74% on the 4-week average of $150.3 million.Source: SEC Form D
- Largest biotech or health care raise: Vesalius Longevity Labs Inc. sold $30.1 million. Pharmaceuticals, Form D filed 3 November 2026.Source: SEC Form D
- New company-sponsored trials: 662 registered. Up 58% on the 4-week average of 419.8.Source: ClinicalTrials.gov
- New company-sponsored Phase 3 trials: 290 registered. Up 52% on the 4-week average of 191.0.Source: ClinicalTrials.gov
- Medicines stepping up a phase: 35 medicines entered a higher trial phase. Tuesday's list has the 12 largest.Source: ClinicalTrials.gov
- Disease with the most new company trials: Multiple Myeloma, 23 new trials.Source: ClinicalTrials.gov
- Medicine approvals: 1 approvals recorded. Down 76% on the 4-week average of 4.3.Source: FDA
- Licensing and partnership deals: 8 deals, $1.3 billion disclosed upfront. Down 56% on the 4-week average of 18.3.Source: Company filings and announcements
How this list is made
Each line compares the 7 days to yesterday with the average of the 4 weeks before; a line is left out while its source has no record for the week yet. Raises are SEC Form D sales by operating biotech, pharmaceutical and health care companies (funds and vehicles left out). Trials are registrations on ClinicalTrials.gov; approvals, clearances and warning letters come from FDA records.
Sources: SEC EDGAR, Form D, ClinicalTrials.gov, FDA.